生物材料
间充质干细胞
生物医学工程
透明质酸
细胞外基质
药物输送
血管生成
材料科学
心力衰竭
缺血
心功能曲线
间质细胞
医学
药理学
心脏病学
病理
癌症研究
细胞生物学
解剖
生物
纳米技术
作者
Chloé Pezzana,Audrey Cras,Fanny SIMELIERE,Rose Guesdon,Manon Desgres,Bruna Lima Correa,Ashley Peuffier,Valérie Bellamy,Sara Gouarderes,A. Alberdi,Marie‐Cécile Perier,Laetitia Pidial,Florence Agnely,Amélie Bochot,Albert Hagège,Jean‐Sébastien Silvestre,Philippe Menasché
出处
期刊:Biomaterials
[Elsevier]
日期:2022-12-01
卷期号:291: 121877-121877
被引量:8
标识
DOI:10.1016/j.biomaterials.2022.121877
摘要
Extracellular vesicles (EV) are increasingly recognized as a therapeutic option in heart failure. They are usually administered by direct intramyocardial injections with the caveat of a rapid wash-out from the myocardium which might weaken their therapeutic efficacy. To improve their delivery in the failing myocardium, we designed a system consisting of loading EV into a clinical-grade hyaluronic acid (HA) biomaterial. EV were isolated from umbilical cord-derived mesenchymal stromal cells. The suitability of HA as a delivery platform was then assessed in vitro. Rheology studies demonstrated the viscoelastic and shear thinning behaviors of the selected HA allowing its easy injection. Moreover, the release of HA-embedded EV was sustained over more than 10 days, and EV bioactivity was not altered by the biomaterial. In a rat model of myocardial ischemia reperfusion, we showed that HA-embedded EV preserved cardiac function (echocardiography), improved angiogenesis and decreased both apoptosis and fibrosis (histology and transcriptomics) when compared to intramyocardial administration of EV alone. These data thus strengthen the concept that inclusion of EV into a clinically useable biomaterial might optimize their beneficial effects on post-ischemic cardiac repair.
科研通智能强力驱动
Strongly Powered by AbleSci AI